The Human Research Protection Program and the Institutional Review Board are integral components of the Research Institute that ensure compliance and provide oversights of all research activities involving human subjects at Lancaster General Health.

Institutional Review Board

The Institutional Review Board (IRB) is responsible for recommending approval or disapproval of each proposed research project involving human subjects. IRB approval is necessary before work may begin on research studies.

The IRB reviews all human subject research to assure investigators and research staff comply with established policies and procedures around application, review and reporting processes.

The IRB is comprised of scientific, non-scientific and community members who are responsible for reviewing research protocols, informed consent forms and processes, and adverse events.

For more information on IRB requirements, submission processes, templates policies, and access to IRB Manager (online protocol submission and management tool), please contact:

Toni Phelan, CIP
IRB Coordinator

Human Research Protection Program

HRPP logo

The Human Research Protection Program (HRPP) provides oversight of all research activities involving human subjects at LG Health, ensuring compliance with federal and state laws and regulations, and ethical standards for human research. It also educates researchers and staff and provides outreach to the public.

Investigators and research staff at the Ann B. Barshinger Cancer Institute and the Heart and Vascular Institute conduct most human subject research at LG Health. To view the Human Research Protection Policy Manual, click here.

The Cancer Institute is involved with National Cancer Institute cooperative group research studies, as well as some industry-sponsored research. The majority of Heart and Vascular Institute research is industry-sponsored research in which the hospital or The Heart Group of LG serves as a clinical site.  Typically, staff engage in cardiology research involving investigational devices and pharmaceuticals.

If you have questions, would like to file a complaint or have a suggestion about research at LG Health, please contact a representative of the HRPP at

Share This Page: